- Home
- ATER vs CURX Comparison
ATER vs CURX Comparison
Compare ATER & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATER | CURX |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 7.6M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ATER | CURX |
|---|---|---|
| Price | $0.57 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.0K | ★ 5.8M |
| Earning Date | 01-01-0001 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,045,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.26 |
| 52 Week High | $3.50 | $9.18 |
Technical Indicators
Market Signals| Indicator | ATER | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 54.41 |
| Support Level | $0.52 | $0.39 |
| Resistance Level | $0.62 | $0.42 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 46.07 | 29.85 |
Price Performance
Historical ComparisonAbout ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.